FDA Special Protocol Assessments Illuminate Evolution Of Cancer Endpoints
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s special protocol assessment process is being used overwhelmingly for cancer programs, with more than half of pivotal trial SPAs going to oncologics.